Published in final edited form as:

Contraception. 2014 March ; 89(3): 193–196. doi:10.1016/j.contraception.2013.11.020.

Reduction in Infection-Related Mortality since Modifications in the Regimen of Medical Abortion

James Trussell¹, Deborah Nucatola², Mary Fjerstad³, and E Steve Lichtenberg⁴

¹Office of Population Research, Princeton University, Princeton NJ 08544, USA; and The Hull York Medical School, University of Hull, Hull HU6 1RX, England ²Planned Parenthood Federation of America, New York NY 10001, USA ³WomanCare Global, San Diego, CA 92122

⁴Northwestern University Feinberg School of Medicine, Chicago IL 60611, USA

Abstract

Background—From 2001 to March 2006 Planned Parenthood health centers throughout the United States provided medical abortion by a regimen of oral mifepristone followed 24 to 48 hours later by vaginal misoprostol. In response to concerns about serious infections, in early 2006 Planned Parenthood changed the route of misoprostol administration to buccal and required either routine antibiotic coverage or universal screening and treatment for chlamydia; in July 2007, Planned Parenthood began requiring routine antibiotic coverage for all medical abortions.

Methods—We performed a retrospective analysis of Planned Parenthood cases assessing the rates of mortality caused by infection following medical abortion during a time period when misoprostol was administered vaginally (2001 through March 2006), as compared with the rate from April 2006 to the end of 2012 after a change to buccal administration of misoprostol and after initiation of new infection-reduction strategies.

Results—The mortality rate dropped significantly in the 81-month period after the joint change to 1) buccal misoprostol replacing vaginal misoprostol and 2) either sexually transmitted infection (STI) screening or routine preventative antibiotic coverage (15 month period) or universal routine preventative antibiotic coverage as part of the medical abortion (66 month period), from 1.37/100,000 to 0.00/100,000, $p=0.013$ (difference=1.37/100,000, 95% CI 0.47–4.03 per 100,000).

Conclusion—The infection-caused mortality rate following medical abortion declined by 100% following a change from vaginal to buccal administration of misoprostol combined with screen-and-treat or, far more commonly, routine antibiotic coverage.

Introduction

Planned Parenthood Federation of America is a federation of 71 independent local affiliates operating 738 health centers throughout the United States; 332 now provide medical

© 2013 Elsevier Inc. All rights reserved.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Disclosures The authors report no financial conflicts of interest.

Disclaimer: The findings and conclusions in this presentation are those of the authors and do not necessarily represent the views of Planned Parenthood Federation of America, Inc.

abortion. In 2012, 132,653 women received medical abortions, representing ~40% of first trimester abortions in Planned Parenthood health centers.

Antibiotics have been routinely administered at the time of surgical abortions since the publication of a meta-analysis demonstrating that their use resulted in a 42% reduction in post-abortion infection rates (RR=0.58, 95% CI 0.47-0.71).¹ When medical abortion was first introduced, infection risk was believed to be low and lower than for surgical abortion because the method was not invasive of the uterus (unless the procedure fails, when follow-up uterine evacuation is required). However, it is clear that serious infections do occur, albeit infrequently.²⁻⁵

Between 2001 and late 2005, four women in the United States and one in Canada had died from a rare bacterial infection, *Clostridium sordellii*, following medical abortion with mifepristone and misoprostol;⁶ an additional death occurred in the United States in early 2006 from *Clostridium perfringens*. In contrast, no such deaths had been reported in Europe, where medical abortion had been available longer and far more women had used it. One hypothesis for the difference was that vaginal administration of misoprostol was very common in the United States but not as common in Europe.⁷ Another hypothesis was that peri-procedural antibiotics were very commonly provided in the United Kingdom but not in the United States. A final hypothesis is that deaths did occur but were not reported. These infections are rare; little is known about the epidemiology except that women are at highest risk of *C. sordellii* following the end of pregnancy (live birth, medical or surgical abortion, or spontaneous abortion).⁸

Prompted by the deaths following medical abortion and internal data showing a higher than expected serious infection rate (4.5 times the previously published serious infection rate from Planned Parenthood data of 2 per 10,000⁵), Planned Parenthood changed its medical abortion protocol at the end of March 2006. Vaginal administration of misoprostol was discontinued and replaced by buccal administration, and all health centers were required to use one of two strategies intended to reduce the risk of infection: either routine antibiotic coverage or universal screening for chlamydia (and for gonorrhea when considered appropriate), with treatment dependent on test results. After reviewing serious infection rates among health centers using these two different infection-reduction strategies, Planned Parenthood in July 2007 required all health centers to provide routine antibiotic coverage. This report compares rates of mortality before and after these changes.

Materials and Methods

We studied patients having medical abortion at all Planned Parenthood affiliates providing this service at any time during the entire study period 2001-2012. Since 2001, affiliates have reported quarterly the number of patients receiving a medical abortion to the Coalition of Abortion Providers (CAPS) of Planned Parenthood affiliates.

The provisions of FDA approval required any physician who orders, provides, or supervises the provision of mifepristone to sign an agreement with the sole U.S. distributor of mifepristone (Danco Laboratories, LLC) to report all serious adverse events associated with its use.⁹ Serious adverse events include hemorrhage requiring emergency treatment, serious infections, hospitalizations, potentially life-threatening events, and deaths. Danco submits all such reports to the FDA. Planned Parenthood staff was trained in accurate and complete reporting of serious adverse events. Adverse event reports are centrally tracked and monitored by the Coalition of Abortion Providers (CAPS) of Planned Parenthood affiliates.

After March 2006, Planned Parenthood changed the route of administration of misoprostol to buccal (200 mg of mifepristone followed 24 to 48 hours later by 800 µg of buccal misoprostol). In addition, Planned Parenthood health centers providing medical abortion were required either to 1) screen all patients for chlamydia (and gonorrhea if endemic rates or patient history or symptoms indicated need) or 2) provide routine antibiotic coverage with doxycycline orally 100mg BID for 7 days, starting the same day as mifepristone administration. Doxycycline was chosen because it treats chlamydia, the most commonly reported sexually transmitted infection in the United States, and most gonorrhea strains,¹⁰ and provides protection against other organisms that cannot reasonably be tested for. The regimen is not prophylaxis; it was deliberately chosen as a treatment regimen; an antibiotic that specifically targeted *Clostridium* was not chosen. Patients who had a positive test for a sexually transmitted infection were treated with the standard U.S. Centers for Disease Control and Prevention (CDC) treatment recommendations at that time, consisting of doxycycline orally 100 mg BID for 7 days for chlamydia, and ceftriaxone 125 mg intramuscularly in a single dose for gonorrhea.

We analyzed deaths due to infection for the years 2001 to 2012 over two time periods. Period 1 (January 1, 2001 to March 31, 2006) was the baseline 63-month period during which vaginal misoprostol and standard antiseptic measures (hand washing before inserting vaginal misoprostol) were used for medical abortion through 49 (2001-mid 2002) or 63 (mid 2002-March 31, 2006) days of gestation. During this period a few affiliates decided to screen and treat for STIs based on CDC guidelines. Period 2 (April 1, 2006 to December 31, 2012) was the 81-month period during which buccal misoprostol was used through 56 (April 1, 2006- December 31, 2007) or 63 (2008-2012) days of gestation.¹¹ From April 1, 2006 to June 30, 2007, a period of 15 months, some Planned Parenthood clinics used the infection-reduction strategy of universal STI screening and treatment when screening was positive, while others provided routine antibiotic coverage consisting of oral doxycycline 100mg BID for 7 days. Rates of serious infection declined significantly in both groups, but the decline was significantly greater in the routine antibiotics group.¹² Consequently, from July 1, 2007 to the end of 2012, a period of 66 months, routine antibiotic coverage was universally provided (in the group that initially adopted screen-and-treat, there was a further significant drop in the serious infection rate in the second half of 2007 to the same level observed in the group that initially adopted routine antibiotic coverage¹²). Rates of mortality due to infection were compared in the two periods.

Fisher's exact test was used to assess the significance of differences in proportions. Calculations were performed in StatXact (Cytel Inc, Boston Massachusetts). The Princeton Institutional Review Board approved the study protocol and design as a retrospective analysis of data routinely collected for quality control.

Results

From 2001 through 2012, there were 930,484 Planned Parenthood medical abortions, 218,928 in Period 1 and 711,556 in Period 2. There were three deaths due to infection (two *Clostridium sordellii* and one *Clostridium perfringens*) in Period 1 and none in Period 2. The death rate due to infection declined significantly ($p=0.013$) from Period 1 (1.37/100,000) to Period 2 (0.00/100,000) (difference=1.37/100,000, 95% CI 0.47-4.03 per 100,000).

Discussion

We observed a statistically significant and clinically important reduction in the risk of death from infection following medical abortion after a change from vaginal to buccal administration of misoprostol and the adoption of new infection-reduction strategies to

reduce endometritis and sepsis caused by infection, primarily routine antibiotic coverage with a treatment regimen. Although the observational design of our study precludes a determination of cause and effect, it is plausible that both the change in the route of misoprostol administration and antibiotic coverage contributed to the reduction in the mortality rate. However, because strains of bacteria in the environment can change over time, it is possible that the deaths from *C. sordellii* occurred during an unrelated increase in the most virulent strains that later also inexplicably decreased around the time the new medical abortion regimen was adopted. It is important to note that death from infection following medical abortion was rare even before this change in regimen, much rarer than all-cause pregnancy-related mortality.¹³

Potential limitations of our study should be noted. It is possible that deaths due to infection following medical abortion initiated at a Planned Parenthood health center were underreported. However, underreporting is unlikely due to the clinical magnitude of mortality events, the national prominence of the Planned Parenthood identity, Planned Parenthood's meticulous internal system of adverse event reporting combined with strict adherence to FDA requirements for adverse event reporting, and the scientific and societal interest that have attended these mortality events. We also cannot separately assess the associations between the observed mortality reduction and the two interventions—change in the route of administration of misoprostol from vaginal to buccal and the adoption of new infection control measures (dominated in our study by routine administration of antibiotics)—because they were introduced simultaneously.

Finally, women had the option throughout the study period of oral misoprostol through 49 days of gestation. We cannot separately identify the number of medical abortions with oral misoprostol in the two periods; we do know, however, that in all three deaths, vaginal misoprostol was used. In a Planned Parenthood study of the effectiveness of medical abortion with buccal misoprostol in the period immediately after it was adopted, 17% of women used oral misoprostol.¹⁴ The fact that 98% of patients utilizing the oral route came from just two of the ten clinic sites suggests that most sites gave misoprostol by the buccal route to all patients. We think it is highly unlikely that use of oral misoprostol was nearly this high throughout the study period (indeed internal data from affiliate surveys indicate that at least 99% of the medical abortions performed during 2009 and 2010 followed the buccal regimen¹⁵), but even if the number of medical abortions in each period is reduced by 17%, the p-value for the difference in mortality rates due to infection remains unchanged (p=0.013).

Our study reflects medical abortions provided only by Planned Parenthood health centers. Altogether, worldwide, 13 deaths from infection following medical abortion (8 in the United States, 7 from *C. sordellii* and 1 from *C. perfringens*; 1 in Canada from *C. sordellii*; 2 in England & Wales, both from *C. septicum*; 1 in Portugal from *C. sordellii*; 1 in Australia from Grp A *Strep pyogenes*) have been reported: 9 with vaginal misoprostol and no antibiotics, 1 with misoprostol route unknown and no antibiotics, 2 with buccal misoprostol and no antibiotics, and 1 with vaginal misoprostol and doxycycline (personal communication, Daniel Davis MD, FDA, August 20, 2013). Thus, all reported infection-related mortalities during first-trimester medical abortion in the United States and worldwide have used regimens that employed misoprostol by the vaginal route or did not use antibiotics at the time of mifepristone ingestion.

Acknowledgments

We wish to acknowledge all Planned Parenthood staff for their conscientious work and Mimi Tannen, NP, PPFA Consultant.

Funding: This work was supported in part by the Eunice Kennedy Shriver National Institute of Child Health and Human Development grant for Infrastructure for Population Research at Princeton University, Grant R24HD047879 (JT).

References

1. Sawaya GF, Grady D, Kerlikowske K, Grimes DA. Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis. *Obstet Gynecol.* 1996; 87:884–90. [PubMed: 8677129]
2. Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. *N Engl J Med.* 1998; 338:1241–7. [PubMed: 9562577]
3. Hausknecht R. Mifepristone and misoprostol for early medical abortion: 18 months experience in the United States. *Contraception.* 2003; 67:463–5. [PubMed: 12814815]
4. Shannon C, Brothers LP, Philip NM, Winikoff B. Infection after medical abortion: a review of the literature. *Contraception.* 2004; 70:183–90. [PubMed: 15325886]
5. Henderson JT, Hwang AC, Harper CC, Stewart FH. Safety of mifepristone abortions in clinical use. *Contraception.* 2005; 72:175–8. [PubMed: 16102550]
6. Fischer M, Bhatnagar J, Guarner J, et al. Fatal toxic shock syndrome associated with *Clostridium sordellii* after medical abortion. *N Engl J Med.* 2005; 353:2352–60. [PubMed: 16319384]
7. Darney PD. Letter to the editor on deaths associated with medication abortion. *Contraception.* 2005; 72:319. [PubMed: 16181979]
8. [Accessed November 15, 2013] <http://www.cdc.gov/hai/organisms/csordellii.html>
9. <http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111364.pdf>
10. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2006 Supplement, Gonococcal Isolate Surveillance Project (GISP) Annual Report 2006. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; Atlanta, GA: Apr. 2008
11. Winikoff B, Dzuba IG, Creinin MD, Crowden WA, Goldberg AB, Gonzales J, Howe M, Moskowitz J, Prine L, Shannon CS. Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial. *Obstet Gynecol.* 2008; 112:1303–10. [PubMed: 19037040]
12. Fjerstad M, Trussell J, Sivin I, Lichtenberg ES, Cullins V. Rates of serious infection after changes in regimens for medical abortion. *N Engl J Med.* 2009; 361:145–51. [PubMed: 19587339]
13. Berg CJ, Callaghan WM, Syverson C, Henderson Z. Pregnancy-related mortality in the United States, 1998 to 2005. *Obstet Gynecol.* 2010; 116:1302–9. [PubMed: 21099595]
14. Fjerstad M, Sivin I, Lichtenberg ES, Trussell J, Cleland K, Cullins V. Effectiveness of medical abortion with mifepristone and buccal misoprostol through 59 gestational days. *Contraception.* 2009; 80:282–6. [PubMed: 19698822]
15. Cleland K, Creinin MD, Nucatola D, Nshom M, Trussell J. Significant adverse events and outcomes after medical abortion. *Obstet Gynecol.* 2013; 121:166–71. [PubMed: 23262942]

Significance: Deaths from infection following medical abortion declined to zero after a change in the regimen.